Livial Tablets

Livial 2.5mg tablets contain the active substance tibolone, a hormone replacement therapy (HRT) specifically designed for postmenopausal women. This treatment helps relieve common menopausal symptoms like hot flushes, night sweats, and vaginal discomfort, while also helping to prevent osteoporosis (bone thinning). Livial is different from other HRTs as it contains tibolone, which your body converts into hormones that have beneficial effects on various tissues. Available only with a prescription, Livial is suitable for women who are at least 12 months past their last natural period. Learn more about menopause treatment options.
Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £15.00 via Klarna
Tracked 24 Delivery3 interest-free payments via KlarnaDiscreet packaging

Livial Treatment

Product NameLivial
ManufacturerOrganon Pharma (UK) Limited
Active IngredientTibolone
AdministrationOral tablet
PresentationWhite tablets marked "Organon*" on one side and "MK2" on the other
Available Strengths2.5mg / 28 tablets
Product TypePOM — Prescription Only
Starting Price£45.00
Suitable for pregnancy?No - Contraindicated
Use with alcoholConsult your doctor
Link to Patient Information LeafletLivial PIL ↗
Authored byNabeel

Medical Content Manager

Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.

Medical Doctor

Dr. Talal is a GMC registered doctor and medical reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.

Approved byUsman

Medical Director

Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.

Review Date: 2 Jul 2026

Next Review: 1 Jan 2027

Published on: 19 Nov 2025

Last Updated: 3 Jul 2026